Literature DB >> 19149685

Pregnane X receptor and its potential role in drug resistance in cancer treatment.

Yakun Chen1, Daotai Nie.   

Abstract

Multi-drug resistance (MDR) is a significant barrier to effective chemotherapy of cancer. The induction of drug metabolizing enzymes (DMEs) and efflux transporters has been regarded as one of the major mechanisms of drug resistance. As a master transcription factor of DMEs and efflux transporters, pregnane X receptor (PXR), an orphan nuclear receptor known for its activation by structurally diverse compounds, is expressed in some cancer cells and tissues, and is implicated as a novel master regulator of MDR in cancers. This review describes recent publications and patents on the mechanism of PXR transcription, the expression of PXR in cancers, and its potential roles in cancer MDR. We also discuss the recent patents published to overcome PXR-mediated MDR and other potential roles of PXR in cancers.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19149685     DOI： 10.2174/157489209787002498

Source DB:  PubMed          Journal:  Recent Pat Anticancer Drug Discov        ISSN： 1574-8928            Impact factor:   4.169


  17 in total

1.  Camptothecin attenuates cytochrome P450 3A4 induction by blocking the activation of human pregnane X receptor.

Authors:  Yakun Chen; Yong Tang; Gregory T Robbins; Daotai Nie
Journal:  J Pharmacol Exp Ther       Date:  2010-05-26       Impact factor: 4.030

Review 2.  Pregnane xenobiotic receptor in cancer pathogenesis and therapeutic response.

Authors:  Satyanarayana R Pondugula; Sridhar Mani
Journal:  Cancer Lett       Date:  2012-08-29       Impact factor: 8.679

3.  Acetylation of lysine 109 modulates pregnane X receptor DNA binding and transcriptional activity.

Authors:  Danielle Pasquel; Aneta Doricakova; Hao Li; Sandhya Kortagere; Matthew D Krasowski; Arunima Biswas; William G Walton; Matthew R Redinbo; Zdenek Dvorak; Sridhar Mani
Journal:  Biochim Biophys Acta       Date:  2016-02-23

Review 4.  Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters.

Authors:  Yakun Chen; Yong Tang; Changxiong Guo; Jiuhui Wang; Debasish Boral; Daotai Nie
Journal:  Biochem Pharmacol       Date:  2012-02-04       Impact factor: 5.858

5.  Pregnane X Receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation.

Authors:  Caroline Raynal; Jean-Marc Pascussi; Géraldine Leguelinel; Cyril Breuker; Jovana Kantar; Benjamin Lallemant; Sylvain Poujol; Caroline Bonnans; Dominique Joubert; Frédéric Hollande; Serge Lumbroso; Jean-Paul Brouillet; Alexandre Evrard
Journal:  Mol Cancer       Date:  2010-03-02       Impact factor: 27.401

Review 6.  PXR: More Than Just a Master Xenobiotic Receptor.

Authors:  Peter O Oladimeji; Taosheng Chen
Journal:  Mol Pharmacol       Date:  2017-11-07       Impact factor: 4.436

7.  High-Throughput Screening Identifies 1,4,5-Substituted 1,2,3-Triazole Analogs as Potent and Specific Antagonists of Pregnane X Receptor.

Authors:  Wenwei Lin; Asli N Goktug; Jing Wu; Duane G Currier; Taosheng Chen
Journal:  Assay Drug Dev Technol       Date:  2017-11-07       Impact factor: 1.738

Review 8.  PXR antagonists and implication in drug metabolism.

Authors:  Sridhar Mani; Wei Dou; Matthew R Redinbo
Journal:  Drug Metab Rev       Date:  2013-02       Impact factor: 4.518

Review 9.  Role of pregnane X receptor in chemotherapeutic treatment.

Authors:  Wei Zhuo; Lei Hu; Jinfeng Lv; Hongbing Wang; Honghao Zhou; Lan Fan
Journal:  Cancer Chemother Pharmacol       Date:  2014-06-03       Impact factor: 3.333

Review 10.  Elucidating the 'Jekyll and Hyde' nature of PXR: the case for discovering antagonists or allosteric antagonists.

Authors:  Arunima Biswas; Sridhar Mani; Matthew R Redinbo; Matthew D Krasowski; Hao Li; Sean Ekins
Journal:  Pharm Res       Date:  2009-05-05       Impact factor: 4.200
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.